| Similar Articles |
|---|
 |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom.   |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
November 9, 2010
Brian Orelli |
Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals. |
The Motley Fool
June 3, 2010
Brian Orelli |
The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development. |
The Motley Fool
September 24, 2008
Brian Orelli |
100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
July 14, 2009
Brian Orelli |
Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics. |
The Motley Fool
December 31, 2008
Brian Orelli |
Health Care's Golden Children The whole industry wasn't down this year. |
The Motley Fool
June 20, 2008
Brian Orelli |
Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics. |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
August 28, 2009
Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
Fast Company
Elizabeth Segran |
23andMe And The FDA Reached A Pivotal Genetic Testing Agreement An FDA decision summary allows DNA-testing company 23andMe to market a genome test that screens for Bloom syndrome, a rare disorder that may lead toward the development of cancer. |
Bio-IT World
April 16, 2004 |
Portraits in Proteomics Advances in identifying protein biomarkers are spurring new hope in cancer diagnostics, expediting detection and easing testing. |
Scientific American
March 2009
Elaine Schattner |
A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Stephen Quake: Innovative Thinking on Genetic Tests His ideas have already led to a blood test to tell a pregnant woman whether her fetus has Down syndrome. Now, the HHMI investigator is pushing further, to track the success of heart transplants and diagnose autoimmune diseases and allergies. |
The Motley Fool
July 9, 2008
Brian Lawler |
Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests. |
The Motley Fool
December 18, 2008
Brian Orelli |
A Diagnostic Tongue Twister Back-scratch fever between Abbott and Isis. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Scientific American
February 2009
Charles Q. Choi et al. |
News Scan Briefs: Weak on the Nano Risk Also: Booby Traps for Bacteria and more... |
Chemistry World
June 9, 2015
Phillip Broadwith |
Opko deepens diagnostics with $1.5bn lab buyout Healthcare firm Opko is aiming to enhance its position in diagnostic technology by agreeing to buy clinical diagnostics service BioReference Laboratories. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
The Motley Fool
January 19, 2011
Brian Orelli |
High Stakes at Tomorrow's FDA Panel Meeting It's more than just Eli Lilly on the line. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Fast Company
David Lumb |
Sites That Sell Cancer Gene Tests Don't Tell Customers The Whole Story, Study Finds Consumer tests that analyze DNA from tumors in order to help personalize a patient's treatment are in something of a Wild West period. |
Bio-IT World
March 2007
Michael A. Greeley |
Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities. |
Chemistry World
February 25, 2015
Rebecca Trager |
US opens up home DNA screening The US Food and Drug Administration has, for the first time, authorized a genetic test to be sold directly to consumers. The agency plans to ease the regulatory path for similar screening tests. |
Chemistry World
August 9, 2012 |
Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials. |
The Motley Fool
February 18, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week?: Seagate Technology... Prospect Capital... Interactive Intelligence... Sequenom... 99 Cents Only Stores... |
Fast Company
November 2013
Elizabeth Murphy |
Inside 23andMe founder Anne Wojcicki's $99 DNA Revolution If Wojcicki gets it right, 23andMe could help change the health care industry as we know it. "At $99, we are opening the doors of access," she says. "Genetics is part of an entire path for how you're going to live a healthier life." |
American Family Physician
August 15, 2000 |
Down Syndrome: What You Need to Know When You're Pregnant |
Managed Care
November 2006
Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
The Motley Fool
September 28, 2007
Brian Orelli |
Side Effects No Match for This Tag Team Seven large drugmakers have come together to try and find genetic variations that cause medications to have serious side effects in some patients, but not in others. |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
Pharmaceutical Executive
January 1, 2009
Amit Agarwal |
Overlooked Opportunities For pharma companies facing a difficult economic climate, pairing diagnostics with therapies offers a powerful incentive: Manufacturers can improve sales by helping physicians find the most appropriate therapeutic option. |
Fast Company
David Lumb |
The FDA Just OK'd 23AndMe To Test For One Syndrome The FDA just gave consumer genetics testing company 23AndMe permission to sell tests for Bloom syndrome -- a disease associated with shortened height and an increased cancer risk. |
The Motley Fool
May 28, 2010
Brian Orelli |
Is It Time to Make Money Investing in Genetic Testing? Easier said than done. |
Bio-IT World
March 2006
Michael A. Greeley |
The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain. |
American Family Physician
October 15, 2005 |
Prenatal Diagnosis: Amniocentesis and CVS An informational patient hand-out on these fetal diagnostic tests. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Pharmaceutical Executive
September 1, 2011
Don Creighton |
Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement. |
The Motley Fool
January 27, 2009
Brian Orelli |
Testing a Recession-Resistant Hypothesis Quest Diagnostic looks poised for growth even in bad times. |
